TransMedics Group, Inc. (TMDX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
TransMedics Group, Inc. (TMDX) Bundle
Whether you're an investor or analyst, this (TMDX) DCF Calculator is your go-to resource for accurate valuation. Featuring real data from TransMedics Group, Inc., you can adjust forecasts and observe the effects in real time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.6 | 25.6 | 30.3 | 93.5 | 241.6 | 378.5 | 593.0 | 929.0 | 1,455.5 | 2,280.2 |
| Revenue Growth, % | 0 | 8.62 | 18.03 | 208.83 | 158.53 | 56.66 | 56.66 | 56.66 | 56.66 | 56.66 |
| EBITDA | -27.9 | -23.2 | -38.5 | -29.0 | -7.6 | -245.6 | -384.8 | -602.8 | -944.4 | -1,479.6 |
| EBITDA, % | -118.34 | -90.31 | -127.18 | -30.99 | -3.15 | -64.89 | -64.89 | -64.89 | -64.89 | -64.89 |
| Depreciation | 1.2 | 1.6 | 2.6 | 4.2 | 8.2 | 21.2 | 33.1 | 51.9 | 81.3 | 127.4 |
| Depreciation, % | 5.18 | 6.15 | 8.74 | 4.49 | 3.38 | 5.59 | 5.59 | 5.59 | 5.59 | 5.59 |
| EBIT | -29.2 | -24.7 | -41.1 | -33.2 | -15.8 | -256.2 | -401.4 | -628.9 | -985.3 | -1,543.5 |
| EBIT, % | -123.51 | -96.46 | -135.93 | -35.48 | -6.53 | -67.69 | -67.69 | -67.69 | -67.69 | -67.69 |
| Total Cash | 80.7 | 125.6 | 92.5 | 201.2 | 394.8 | 378.5 | 593.0 | 929.0 | 1,455.5 | 2,280.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.6 | 6.9 | 5.9 | 27.6 | 63.6 | 98.4 | 154.2 | 241.6 | 378.5 | 593.0 |
| Account Receivables, % | 27.79 | 26.77 | 19.61 | 29.54 | 26.31 | 26 | 26 | 26 | 26 | 26 |
| Inventories | 11.2 | 11.9 | 14.9 | 20.6 | 44.2 | 138.9 | 217.7 | 341.0 | 534.2 | 836.9 |
| Inventories, % | 47.52 | 46.55 | 49.1 | 22.05 | 18.31 | 36.7 | 36.7 | 36.7 | 36.7 | 36.7 |
| Accounts Payable | 7.2 | 1.2 | 6.7 | 3.3 | 12.7 | 50.1 | 78.5 | 123.0 | 192.8 | 302.0 |
| Accounts Payable, % | 30.7 | 4.7 | 21.98 | 3.57 | 5.26 | 13.24 | 13.24 | 13.24 | 13.24 | 13.24 |
| Capital Expenditure | -.2 | -.5 | -3.5 | -11.9 | -179.1 | -76.4 | -119.7 | -187.6 | -293.9 | -460.4 |
| Capital Expenditure, % | -0.69903 | -1.77 | -11.63 | -12.74 | -74.11 | -20.19 | -20.19 | -20.19 | -20.19 | -20.19 |
| Tax Rate, % | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 |
| EBITAT | -29.2 | -24.8 | -41.2 | -33.2 | -14.8 | -253.1 | -396.5 | -621.2 | -973.1 | -1,524.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -38.7 | -30.7 | -38.6 | -71.7 | -235.9 | -400.5 | -589.2 | -923.0 | -1,446.0 | -2,265.4 |
| WACC, % | 12.21 | 12.21 | 12.21 | 12.21 | 12.15 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,665.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2,311 | |||||||||
| Terminal Value | -22,662 | |||||||||
| Present Terminal Value | -12,747 | |||||||||
| Enterprise Value | -16,412 | |||||||||
| Net Debt | 121 | |||||||||
| Equity Value | -16,533 | |||||||||
| Diluted Shares Outstanding, MM | 33 | |||||||||
| Equity Value Per Share | -508.44 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: TransMedics Group, Inc.'s (TMDX) financial data pre-filled to enhance your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and optimizing your time.
Key Features
- Real-Life TMDX Data: Pre-filled with TransMedics Group’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- 1. Access the Model: Download and open the Excel file containing TransMedics Group, Inc. (TMDX) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to assess different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose This Calculator?
- Accurate Data: Up-to-date TransMedics Group financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on (TMDX).
- User-Friendly: Easy-to-navigate design and clear instructions make it accessible for everyone.
Who Should Use This Product?
- Investors: Evaluate TransMedics Group, Inc.'s (TMDX) market position before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess financial forecasts for TMDX.
- Startup Founders: Understand the valuation strategies employed by innovative companies like TransMedics Group, Inc. (TMDX).
- Consultants: Provide detailed valuation insights and reports for clients in the healthcare sector.
- Students and Educators: Utilize real-life case studies to explore and teach valuation principles related to TMDX.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled TransMedics Group, Inc. (TMDX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for TransMedics Group, Inc. (TMDX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to simplify result analysis.